Abstract:AIMS This double-blind, placebo-controlled trial was designed to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y(12) ADP receptor antagonist compared with clopidogrel, during multiple oral dosing in healthy subjects. METHODS Thirty subjects received placebo, prasugrel 5 mg, 10 mg, or 20 mg, or clopidogrel 75 mg orally, daily for 10 days. Platelet aggregation, bleeding time, and prasugrel metabolites were measured and adverse events were recorded. RESULTS Inhibition of ADP-induced platelet aggregation reached steady state by day 3 following prasugrel 10 and 20 mg compared with 5 days for clopidogrel 75 mg or prasugrel 5 mg. Compared with placebo, at 24 h after the last dose of study drug, inhibition of platelet aggregation using (20 microm) ADP was significantly higher in the prasugrel 10 mg group (58.2 +/- 4.9% vs. 9.2 +/- 4.0%, P < 0.001) with no difference in the clopidogrel group (15.7 +/- 6.8% vs. 9.2 +/- 4.0%, P = 0.78). With 5 microm ADP, inhibition of platelet aggregation with prasugrel 10 mg and clopidogrel 75 mg was significantly higher than with placebo (prasugrel 10 mg, 70.5 +/- 4.7%; clopidogrel 75 mg, 36.5 +/- 9.0%; vs. placebo, 11.3 +/- 5.1%; P < 0.0001 and P = 0.02). On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98). There were no clinically significant bleeding events, serious adverse events, or discontinuations of the study drug. CONCLUSIONS Compared with clopidogrel 75 mg, prasugrel 10 mg and 20 mg daily for 10 days resulted in more rapid, more consistent, and higher levels of platelet inhibition.

All-Fiber Generation of Sub-30 Fs Pulses at 1.3-Μm Via Cherenkov Radiation with Entire Dispersion Management

Vector-dispersion Compensation and Pulse Pedestal Cancellation in a Femtosecond Nonlinear Amplification Fiber Laser System.

Femtosecond Mode-locked Fiber Laser at 1 Μm Via Optical Microfiber Dispersion Management

Generation of sub-30 fs pulses from an erbium-doped fiber amplifier at 203 MHz repetition rate

Model atmospheres for type Ia supernovae:

All-Fiber-Based Ultrashort Pulse Generation and Chirped Pulse Amplification Through Parametric Processes

Generation Of Ultra-Stable 50-Fs Pulses Directly From An Er-Doped Fiber Oscillator

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.

All-Fiber High-Power 3 GHz Ultrafast Laser System At 2.0 μm

Sub-50 fs pulses generation from an all-fiber monolithic gain-managed nonlinear amplifier with CFBG-based pre-compressor

“Painting” the target: how local molecular cues define synaptic relationships

High-Power GHz Burst-Mode All-Fiber Laser System with Sub 300 fs Pulse Duration

3 GHz, Yb-fiber laser-based, few-cycle ultrafast source at the Ti:sapphire laser wavelength

Microjoule Level Femtosecond Optical Pulses with Double-Cladding Fiber-Based Nonlinear Chirped-Pulse Amplification

Watt-level 2.8 μm ultrashort pulse generation from an all-fiber Er:ZBLAN fiber amplifier

Single-step self-compression of ultrashort pulses below 20 fs by all-fiber supercontinuum generation

Generation of femtosecond pulses based on efficient frequency doubling of erbium fiber oscillator-amplifier laser

Generation of 8-fs and 13-nJ pulse from a Yb-fiber system with nonlinear-pulse-compression

All-Fiber High Repetition Rate Short Pulse Generation Around 1030Nm

Sub-100 fs pulse generation from dispersion-managed mode-locked Er:ZBLAN fiber laser at 2.8 μm

Generation of a 59 Fs Pulse with a 550 Nm Spectral Range in a Mode-Locked Er-doped Single-Mode Fiber Laser System